TA ČR, SIGMA 4 (Univerzita Karlova), TQ11000058, Nový model metastatických linií nediferencovaného pleomorfního sarkomu, 04–11/2025,

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

MZ, AZV, NU23-08-00071, Geneticky snížená exprese imunitního kontrolního bodu LAIR-1 u tumor specifických T buněk jako nová strategie k překonání rezistence pevných nádorů k adoptivní T buněčné imunoterapii, 2023–2026

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Fakultní nemocnice Motol)

Spoluřešitel: MUDr. Luca Vannucci, Ph.D. (Mikrobiologický ústav AV ČR)

MZ, AZV, NU23J-08-00031, Kombinované možnosti léčby měkkotkáňových sarkomů za účelem překonání rezistence k imunoterapii, 2023–2026

Hlavní řešitel: MUDr. Zuzana Střížová, Ph.D. (Fakultní nemocnice Motol)

MZ, AZV, NU22-03-00300, LL-37 jako nový silný molekulární nástroj pro zvýšení účinnosti ex vivo připravených dendritických buněk v imunoterapii urogenitálních karcinomů, 2022–2025

Hlavní řešitel: Prof. MUDr. Jiřina Bartůňková, Ph.D., MBA (Fakultní nemocnice Motol)

Spoluřešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

TA ČR, GAMA 2 (Univerzita Karlova), 202104/TP01010040, Nová buněčná linie nediferencovaného pleomorfního sarkomu, 2021–2022

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

GA UK, 364218, Izolace, charakterizace a expanze subpopulací lymfocytů infiltrujících nádory ledvin pro vývoj adoptivní buněčné imunoterapie, 2018–2020

Hlavní řešitel: MUDr. Zuzana Střížová, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

Školitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

UK, PRIMUS/MED/12, Příprava polyklonálních cytologických T buněk pro adoptivní buněčnou imunoterapii nádorových onemocnění, 2017–2019

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

MZ, AZV, 16-28135A, Příprava polyklonálních nádorově specifických T buněk pro adoptivní buněčnou imunoterapii karcinomu prostaty, 2016–2019

Hlavní řešitel: Doc. RNDr. Daniel Smrž, Ph.D. (Univerzita Karlova, 2. lékařská fakulta)

Spoluřešitel: Prof. MUDr. Jiřina Bartůňková, Ph.D., MBA (Fakultní nemocnice Motol)

Sushytskyi, L., A. Synytsya, P. Lukac, L. Rajsiglova, P. Capek, R. Pohl, R. Bleha, L. E. Vannucci, D. Smrz, J. Copikova, and P. Kastanek. 2025. Immunologically active cell wall polysaccharides of green microalga Dictyosphaerium chlorelloides (Chlorellacea). Carbohydrate polymers 353:123242. DOI: 10.1016/j.carbpol.2025.123242 (IF 10.7; Q1; D1).

Rajsiglova, L., M. Babic, K. Krausova, P. Lukac, K. Kalkusova, P. Taborska, L. Sojka, J. Bartunkova, D. Stakheev, L. Vannucci, and D. Smrz*. 2024. Immunogenic properties of nickel-doped maghemite nanoparticles and the implication for cancer immunotherapy. Journal of immunotoxicology 21:2416988. DOI: 10.1080/1547691X.2024.2416988 (*corresponding; IF 2.4; Q3; D7).

Kalkusova, K., P. Taborska, D. Stakheev, M. Rataj, S. Smite, E. Darras, J. Albo, J. Bartunkova, L. Vannucci, and D. Smrz*. 2024. Impaired Proliferation of CD8(+) T Cells Stimulated with Monocyte-Derived Dendritic Cells Previously Matured with Thapsigargin-Stimulated LAD2 Human Mast Cells. Journal of immunology research 2024:5537948.  DOI: 10.1155/2024/5537948 (*corresponding; IF 3.5; Q2; D5).

Patent, Úřad průmyslového vlastnictví ČR, č. 310055 – Buněčná linie a její použití, majitel patentu: Univerzita Karlova, původci: Doc. RNDr. Daniel Smrž, Ph.D. a Ing. Pavla Táborská, Ph.D. [přechodná mezinárodní ochrana uplatněna: PCT/CZ2023/050092, WO 2024/132002 A1, Univerzita Karlova]

Borcinova, M., R. Bartolini, L. K. Foley, V. Novak, P. Taborska, D. Stakheev, M. Rataj, D. Smrz, M. Fialova, J. Hacek, M. Komarc, S. Vesely, M. Babjuk, I. Striz, J. Bartunkova, T. Buchler, and Z. Ozaniak Strizova*. 2024. Distinct leukocyte populations and cytokine secretion profiles define tumoral and peritumoral areas in renal cell carcinoma. Translational oncology 42:101891. DOI:10.1016/j.tranon.2024.101891 (*corresponding, IF 4.5; Q1; D3).

Taborska, P., P. Lukac, D. Stakheev, L. Rajsiglova, K. Kalkusova, K. Strnadova, L. Lacina, B. Dvorankova, J. Novotny, M. Kolar, M. Vrana, H. Cechova, S. Ransdorfova, M. Valerianova, K. Smetana, Jr., L. Vannucci, and D. Smrz*. 2023. Novel PD-L1- and collagen-expressing patient-derived cell line of undifferentiated pleomorphic sarcoma (JBT19) as a model for cancer immunotherapy. Scientific reports 13:19079. DOI: 10.1038/s41598-023-46305-7 (*corresponding; IF 3.8; Q1; D2).

Stakheev, D., P. Taborska, K. Kalkusova, J. Bartunkova, and D. Smrz*. 2022. LL-37 as a Powerful Molecular Tool for Boosting the Performance of Ex Vivo-Produced Human Dendritic Cells for Cancer Immunotherapy. Pharmaceutics 14. DOI: 10.3390/pharmaceutics14122747 (*corresponding; IF 5.4; Q1, D2).

Kalkusova, K., P. Taborska, D. Stakheev, and D. Smrz*. 2022. The Role of miR-155 in Antitumor Immunity. Cancers 14. DOI: 10.3390/cancers14215414 (*corresponding; IF 5.2; Q1; D3).

Kalkusova, K., S. Smite, E. Darras, P. Taborska, D. Stakheev, L. Vannucci, J. Bartunkova, and D. Smrz*. 2022. Mast Cells and Dendritic Cells as Cellular Immune Checkpoints in Immunotherapy of Solid Tumors. International journal of molecular sciences 23. DOI: 10.3390/ijms231911080 (*corresponding; IF 5.6; Q1; D3).

Podrazil, M., P. Taborska, D. Stakheev, M. Rataj, J. Lastovicka, A. Vlachova, P. Pohunek, J. Bartunkova, and D. Smrz*. 2022. Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. Frontiers in immunology 13:892277. DOI: 10.3389/fimmu.2022.892277 (*corresponding; IF 7.3; Q1; D3).

Bugajev, V., T. Paulenda, P. Utekal, M. Mrkacek, I. Halova, L. Kuchar, O. Kuda, P. Vavrova, B. Schuster, S. Fuentes-Liso, L. Potuckova, D. Smrz, S. Cernohouzova, L. Draberova, M. Bambouskova, and P. Draber. 2021. Crosstalk between ORMDL3, serine palmitoyltransferase, and 5-lipoxygenase in the sphingolipid and eicosanoid metabolic pathways. J Lipid Res:100121. 10.1016/j.jlr.2021.100121 (IF 6.6; Q1; D3).

Taborska, P., J. Lastovicka, D. Stakheev, Z. Strizova, J. Bartunkova, and D. Smrz*. 2021. SARS-CoV-2 spike glycoprotein-reactive T cells can be readily expanded from COVID-19 vaccinated donors. Immunity, inflammation and disease.10.1002/iid3.496 (*corresponding; IF 2.4; Q4; D9).

Bezdicka, M., P. Kleiblova, J. Soucek, M. Borecka, E. El-Lababidi, D. Smrz, M. Rataj, Z. Sumnik, J. Malikova, and O. Soucek. 2021. Novel presentation of the c.1856A > G (p.Asp619Gly) TSHR gene-activating variant: relapsing hyperthyroidism in three subsequent generations manifesting in early childhood and an in vitro functional study. Hormones.10.1007/s42000-021-00299-x (IF 3.4; Q3; D7).

Taborska, P., Z. Strizova, D. Stakheev, L. Sojka, J. Bartunkova, and D. Smrz*. 2021. CD4(+) T Cells of Prostate Cancer Patients Have Decreased Immune Responses to Antigens Derived From SARS-CoV-2 Spike Glycoprotein. Frontiers in immunology 12:629102.10.3389/fimmu.2021.629102 (*corresponding; IF 8.8; Q1; D3).

Taborska, P., D. Stakheev, J. Bartunkova, and D. Smrz*. 2021. Thapsigargin-Stimulated LAD2 Human Mast Cell Line Is a Potent Cellular Adjuvant for the Maturation of Monocyte-Derived Dendritic Cells for Adoptive Cellular Immunotherapy. International journal of molecular sciences 22. 22.10.3390/ijms22083978 (*corresponding; IF 6.2; Q1; D3).

Snajdauf, M., K. Havlova, J. Vachtenheim, Jr., A. Ozaniak, R. Lischke, J. Bartunkova, D. Smrz, and Z. Strizova*. 2021. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Frontiers in molecular biosciences 8:628332. 10.3389/fmolb.2021.628332 (*corresponding; IF 6.1; Q1; D3).

Strizova, Z., M. Kuchar, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, J. Plzak, and D. Smrz*. 2021. Fas-Fas Ligand Interplay in the Periphery of Salivary Gland Carcinomas as a New Checkpoint Predictor for Disease Severity and Immunotherapy Response. Biomedicines 9. 10.3390/biomedicines9040402 (*corresponding; IF 4.7; Q2; D5).

Mucciolo, G., C. Curcio, C. Roux, W. Y. Li, M. Capello, R. Curto, R. Chiarle, D. Giordano, M. A. Satolli, R. Lawlor, A. Scarpa, P. Lukac, D. Stakheev, P. Provero, L. Vannucci, T. W. Mak, F. Novelli, and P. Cappello. 2021. IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. Proc Natl Acad Sci U S A 118. DOI: 10.1073/pnas.2020395118 (IF 12.7; Q1; D2).

Kuchar, M., Z. Strizova*, L. Capkova, M. Komarc, J. Skrivan, J. Bartunkova, D. Smrz, and J. Plzak. 2021. The Periphery of Salivary Gland Carcinoma Tumors Reveals a PD-L1/PD-1 Biomarker Niche for the Evaluation of Disease Severity and Tumor-Immune System Interplay. Biomedicines 9. DOI: 10.3390/biomedicines9020097 (*corresponding, IF 4.7; Q2; D5).

Taborska, P., D. Stakheev, H. Svobodova, Z. Strizova, J. Bartunkova, and D. Smrz*. 2020. Acute Conditioning of Antigen-Expanded CD8(+) T Cells via the GSK3beta-mTORC Axis Differentially Dictates Their Immediate and Distal Responses after Antigen Rechallenge. Cancers 12. 10.3390/cancers12123766 (*corresponding, IF 6.6; Q1; D3).

Strizova, Z*., D. Smrz, and J. Bartunkova. 2020. Response to Weiss MF re: "Seroprevalence of Borrelia IgM and IgG Antibodies in Healthy Individuals: A Caution Against Serology Misinterpretations and Unnecessary Antibiotic Treatments". Vector Borne Zoonotic Dis. 10.1089/vbz.2020.2690 (*corresponding, IF 2.1; Q4; D9).

Strizova, Z., J. Vachtenheim, Jr., M. Snajdauf, R. Lischke, J. Bartunkova, and D. Smrz*. 2020. Tumoral and paratumoral NK cells and CD8(+) T cells of esophageal carcinoma patients express high levels of CD47. Scientific reports 10:1393 (*corresponding, IF 4.3; Q1; D2).

Ozaniak, A., Z. Strizova, P. Hladik, and R. Lischke. 2020. Novel therapeutic approaches in the treatment of solitary fibrous tumors: A call for a combination therapy. Cancer 126:4068-4069

Strizova, Z.*, J. Bartunkova, and D. Smrz. 2020. Can wearing face masks in public affect transmission route and viral load in COVID-19? Central European journal of public health 28:161-162 (*corresponding, IF 1.1; Q4; D10).

Paces, J., Z. Strizova*, D. Smrz, and J. Cerny. 2020. COVID-19 and the immune system. Physiological research. 10.33549/physiolres.934492 (*corresponding, IF 1.8; Q4; D9).

Strizova, Z., M. Snajdauf, D. Stakheev, P. Taborska, J. Vachtenheim, Jr., J. Biskup, R. Lischke, J. Bartunkova, and D. Smrz*. 2020. The paratumoral immune cell signature reveals the potential for the implementation of immunotherapy in esophageal carcinoma patients. Journal of cancer research and clinical oncology 146:1979-1992 (*corresponding, IF 4.5; Q2; D5).

Strizova, Z., T. Milota, and J. Bartunkova. 2020. COVID-19 from the perspective of an immunologist. Casopis lekaru ceskych 159:67-71

Strizova, Z.*, D. Smrz, and J. Bartunkova. 2020. Seroprevalence of Borrelia IgM and IgG Antibodies in Healthy Individuals: A Caution Against Serology Misinterpretations and Unnecessary Antibiotic Treatments. Vector Borne Zoonotic Dis. 10.1089/vbz.2020.2632 (*corresponding, IF 2.1; Q4; D9).

Tobio, A., G. Bandara, D. A. Morris, D. K. Kim, M. P. O'Connell, H. D. Komarow, M. C. Carter, D. Smrz, D. D. Metcalfe, and A. Olivera. 2020. Oncogenic D816V-KIT signaling in mast cells causes persistent IL-6 production. Haematologica 105:124-135 (IF 9.9; Q1; D1).

Kuchar, M., Z. Strizova, M*. Votava, and J. Plzak. 2019. The relevance of Fas/Fas ligand axis in the tumor microenvironment of salivary gland adenoid cystic carcinoma. Oral oncology 97:135-136 (*corresponding, IF 3.9; Q1; D1).

Strizova, Z.*, J. Vachtenheim, Jr., and J. Bartunkova. 2019. The potential role of neutrophil trogocytosis and G-CSF in the loss of HER2 expression. Breast Cancer Res Treat 178:247-248 (*corresponding, IF 3.8; Q2; D4).

Strizova, Z., J. Bartunkova, and D. Smrz*. 2019. The challenges of adoptive cell transfer in the treatment of human renal cell carcinoma. Cancer immunology, immunotherapy : CII 68:1831-1838 (*corresponding, IF 5.4; Q1; D3).

Strizova, Z., P. Taborska, D. Stakheev, S. Partlova, K. Havlova, S. Vesely, J. Bartunkova, and D. Smrz*. 2019. NK and T cells with a cytotoxic/migratory phenotype accumulate in peritumoral tissue of patients with clear cell renal carcinoma. Urologic oncology 37:503-509 (*corresponding, IF 2.8; Q3; D6).

Stakheev, D., P. Taborska, Z. Strizova, M. Podrazil, J. Bartunkova, and D. Smrz*. 2019. The WNT/beta-catenin signaling inhibitor XAV939 enhances the elimination of LNCaP and PC-3 prostate cancer cells by prostate cancer patient lymphocytes in vitro. Scientific reports 9:4761 (*corresponding, IF 4.0; Q1; D3).

Strizova, Z.*, O. Patek, L. Vitova, M. Horackova, and J. Bartunkova. 2019. Internet-based self-diagnosis of Lyme disease caused death in a young woman with systemic lupus erythematosus. Joint, bone, spine : revue du rhumatisme 86:650-651 (*corresponding, IF 3.7; Q2; D4).

Taborska, P., J. Bartunkova, and D. Smrz*. 2018. Simultaneous in vitro generation of human CD34(+)-derived dendritic cells and mast cells from non-mobilized peripheral blood mononuclear cells. J Immunol Methods 458:63-73 (*corresponding, IF 1.9; Q3; D7).

Taborska, P., D. Stakheev, Z. Strizova, K. Vavrova, M. Podrazil, J. Bartunkova, and D. Smrz*. 2017. Personalized ex vivo multiple peptide enrichment and detection of T cells reactive to multiple tumor-associated antigens in prostate cancer patients. Medical oncology 34:173 (*corresponding, IF 2.9; Q3; D6).